Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Natera, Inc. (NASDAQ:NTRA – Get Rating) CFO Michael Burkes Brophy sold 429 shares of the business’s stock in a transaction on Friday, December 23rd. The shares were sold at an average price of $42.30, for a total transaction of $18,146.70. Following the transaction, the chief financial officer now owns 89,974 shares in the company, valued at $3,805,900.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, October 24th, Michael Burkes Brophy sold 2,488 shares of Natera stock. The shares were sold at an average price of $42.41, for a total transaction of $105,516.08.
- On Wednesday, September 28th, Michael Burkes Brophy sold 915 shares of Natera stock. The shares were sold at an average price of $44.04, for a total transaction of $40,296.60.
Natera Stock Performance
Natera stock traded down $1.22 on Tuesday, reaching $40.32. 683,663 shares of the stock were exchanged, compared to its average volume of 1,713,473. The firm has a fifty day moving average price of $40.61 and a two-hundred day moving average price of $43.54. Natera, Inc. has a twelve month low of $26.10 and a twelve month high of $95.51. The company has a current ratio of 3.10, a quick ratio of 2.95 and a debt-to-equity ratio of 0.78. The stock has a market cap of $3.94 billion, a PE ratio of -7.10 and a beta of 1.29.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Crossmark Global Holdings Inc. bought a new position in shares of Natera during the 1st quarter worth about $246,000. Bank of New York Mellon Corp increased its holdings in shares of Natera by 6.7% during the 1st quarter. Bank of New York Mellon Corp now owns 820,974 shares of the medical research company’s stock worth $33,399,000 after purchasing an additional 51,791 shares during the period. US Bancorp DE increased its holdings in shares of Natera by 20.0% during the 1st quarter. US Bancorp DE now owns 16,180 shares of the medical research company’s stock worth $658,000 after purchasing an additional 2,698 shares during the period. Nwam LLC increased its holdings in shares of Natera by 51.0% during the 1st quarter. Nwam LLC now owns 11,850 shares of the medical research company’s stock worth $482,000 after purchasing an additional 4,000 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Natera during the 1st quarter worth about $2,312,000. Institutional investors own 93.81% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. Stephens reduced their price objective on shares of Natera to $67.00 in a research note on Wednesday, November 16th. StockNews.com assumed coverage on shares of Natera in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. Credit Suisse Group reduced their price objective on shares of Natera from $70.00 to $55.00 and set an “outperform” rating for the company in a research note on Monday, November 14th. BTIG Research reduced their price objective on shares of Natera from $95.00 to $75.00 in a research note on Wednesday, November 9th. Finally, Robert W. Baird reduced their price objective on shares of Natera from $72.00 to $65.00 in a research note on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.82.
About Natera
(Get Rating)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading
- Get a free copy of the StockNews.com research report on Natera (NTRA)
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Natera, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Natera wasn’t on the list.
While Natera currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by entering your email address below.
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
